US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Franklin Genomic Advancements ETF

43.79

+0.26000.60%

Post-market: 43.790.00000.00%16:10 EDT

Volume:4K

Turnover:165.34K

Market Cap:32.84M

PE:- -

High:43.87

Open:43.69

Low:43.61

Close:43.53

52wk High:44.89

52wk Low:31.44

Shares:750.00K

Float Shares:750.00K

Volume Ratio:0.13

T/O Rate:0.50%

Dividend:0.14

Dividend Rate:0.32%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

AI-Driven Lung Cancer Screening Advances Precision Medicine, Boosting Opportunities for TH MEDICAL-B (02697)

Asymchem shares surge 5% on plan to inject 1.05 billion yuan into biotech subsidiary

Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky Disposes of 1,299 Common Shares for $31,176

ClearPoint Neuro reports Q2 EPS (38c), consensus (29c)

ClearPoint Neuro Q2 Revenue Rises 18% but Misses Estimates

GeneDx Q2 Revenue Beats Analyst Estimates

Krystal Biotech Down Nearly 12%, on Pace for Largest Percent Decrease Since August 2025

Wall Street Analysts Are Bullish on Top Healthcare Picks

Analysts Conflicted on These Healthcare Names: Guardant Health (GH) and Cardinal Health (CAH)

Krystal Biotech Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Design Therapeutics Q2 Net Loss Narrower than Expected

Ocular Therapeutix Q2 Product Revenue Flat, Net Loss Widens on Higher Spending

Krystal Biotech Q2 Revenue Rises on Vyjuvek Strength

Krystal Biotech Shares Down 5.8% Premarket After Q2 Results

THOMSON REUTERS

Krystal Biotech Q2 Net Income Rises 43% to $54.8 Million; Revenue Climbs 24% to $119.2 Million

Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results

THOMSON REUTERS

Krystal Biotech - Sees FY 2026 Non-Gaap R&D and SG&a Expense $175 Mln-$195 Mln

THOMSON REUTERS

Krystal Biotech Q2 Product Revenue USD 119.222 Million

THOMSON REUTERS

Guardant Health Shares Climb Following Outlook Raise

RBC Raises Price Target on Guardant Health to $200 From $185, Keeps Outperform Rating

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/HELX/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"HELX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","market":"US","secType":"STK","nameCN":"Franklin Genomic Advancements ETF","latestPrice":43.79,"timestamp":1790971200000,"preClose":43.53,"halted":0,"volume":3777,"hourTrading":{"tag":"盘后","latestPrice":43.79,"preClose":43.79,"latestTime":"16:10 EDT","volume":7,"amount":306.53,"timestamp":1790971805380,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.005972892258212681,"floatShares":750000,"shares":750000,"eps":0,"marketStatus":"Market Closed","change":0.26,"latestTime":"10-02 16:00:00 EDT","open":43.69,"high":43.865,"low":43.605,"amount":165337,"amplitude":0.005973,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"exchange":"CBOE","adjPreClose":43.53,"sharesOutstanding":650000,"nav":43.859,"aum":32894030.1,"dividendRate":0.003238,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":43.79,"preClose":43.79,"latestTime":"16:10 EDT","volume":7,"amount":306.53,"timestamp":1790971805380,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.12822514959299489,"impliedVol":0.052,"impliedVolPercentile":0.0359},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","floatShares":750000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.12822514959299489,"shares":750000,"dividePrice":0.1418,"high":43.865,"amplitude":0.005973,"preClose":43.53,"low":43.605,"week52Low":31.44,"pbRate":"--","week52High":44.89,"institutionHeld":0,"latestPrice":43.79,"eps":0,"divideRate":0.003238,"volume":3777,"delay":0,"ttmEps":0,"open":43.69,"prevYearClose":36.3062,"prevWeekClose":44.296,"prevMonthClose":44.5641,"prevQuarterClose":44.5641,"fiveDayClose":44.296,"twentyDayClose":42.3102,"sixtyDayClose":40.4693},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HELX\",params:#limit:5,,,undefined,":[{"date":"2025-12-30","symbol":"HELX","amount":0.14334,"announcedDate":"2025-12-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-30","defaultRemindTime":1767105000000,"name":"Franklin Genomic Advancements ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-08","payableDate":"2025-12-30","currency":"USD","dateTimestamp":1767070800000,"payDate":"2026-01-08"},{"market":"US","date":"2021-12-30","symbol":"HELX","amount":0.003935,"defaultRemindTime":1640874600000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2022-01-07","payableDate":"2021-12-31","currency":"USD","type":"dividend","dateTimestamp":1640840400000},{"market":"US","date":"2021-12-13","symbol":"HELX","amount":0.114148,"defaultRemindTime":1639405800000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2021-12-21","payableDate":"2021-12-14","currency":"USD","type":"dividend","dateTimestamp":1639371600000},{"market":"US","date":"2020-12-14","symbol":"HELX","amount":0.005005,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2020-12-23","payableDate":"2020-12-15","currency":"USD","type":"dividend","dateTimestamp":1607922000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HELX\",market:\"US\",,,undefined,":[{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-23","value":0.005005,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-21","value":0.114148,"currency":"USD"},{"executeDate":"2021-12-30","recordDate":"2021-12-31","paymentDate":"2022-01-07","value":0.003935,"currency":"USD"},{"executeDate":"2025-12-30","recordDate":"2025-12-30","paymentDate":"2026-01-08","value":0.14334,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HELX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HELX\",pageSize:20,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1103326040","title":"AI-Driven Lung Cancer Screening Advances Precision Medicine, Boosting Opportunities for TH MEDICAL-B (02697)","url":"https://stock-news.laohu8.com/highlight/detail?id=1103326040","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103326040?lang=en_us&edition=fundamental","pubTime":"2026-08-04 13:03","pubTimestamp":1785819824,"startTime":"0","endTime":"0","summary":"The integration of cutting-edge technologies like artificial intelligence and medical robotics into clinical diagnostics is driving breakthroughs in early lung cancer screening and precision...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNOM","BMED","DTEC","CHAT","QTOC","TYNE","AIPO","KOMP","SYNB","GNMX","ARTY","XT","HELX","HTEC","02697","VTHR","AGIX","IDNA","159891","BK1100","WDNA","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121045193","title":"Asymchem shares surge 5% on plan to inject 1.05 billion yuan into biotech subsidiary","url":"https://stock-news.laohu8.com/highlight/detail?id=1121045193","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121045193?lang=en_us&edition=fundamental","pubTime":"2026-08-04 09:28","pubTimestamp":1785806898,"startTime":"0","endTime":"0","summary":"Asymchem (06821) opened more than 5% higher on the Hong Kong Stock Exchange on Monday, with shares trading up 5.5% to HK$115 as of press time, on a turnover of HK$3.197 million.The company, known as...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VXUS","002821","06821","BK4585","BK1191","BK4588","LU1328615791.USD","WDNA","BK0239","BK0132","HELX","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656300573","title":"Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky Disposes of 1,299 Common Shares for $31,176","url":"https://stock-news.laohu8.com/highlight/detail?id=2656300573","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656300573?lang=en_us&edition=fundamental","pubTime":"2026-08-04 06:27","pubTimestamp":1785796048,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky disposes of 1,299 common shares for $31,176Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky sold 1,299 common shares on","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDLbC3PX5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky Disposes of 1,299 Common Shares for $31,176","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADPT","BK4121","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656302838","title":"ClearPoint Neuro reports Q2 EPS (38c), consensus (29c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2656302838","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656302838?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:40","pubTimestamp":1785789624,"startTime":"0","endTime":"0","summary":"Reports Q2 revenue $10.88M, consensus $12.73M. “Establishing ClearPoint Neuro (CLPT) as the leading neuro cell and gene therapy delivery company ha...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/clearpoint-neuro-reports-q2-eps-38c-consensus-29c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/clearpoint-neuro-reports-q2-eps-38c-consensus-29c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLPT","LFSC","WDNA","FBT","IDNA","BK4585","GNOM","TBXU","SYNB","BK4082","BK4588","JDOC","CNCR","IBBQ","IBB","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656083301","title":"ClearPoint Neuro Q2 Revenue Rises 18% but Misses Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2656083301","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656083301?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:14","pubTimestamp":1785788065,"startTime":"0","endTime":"0","summary":"ClearPoint Neuro Q2 revenue rises 18% but misses estimatesOverviewDevice and gene therapy-enabling firm's Q2 revenue rose 18% yr/yr but missed analyst expectationsGross margin improved to 62% from 60%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL1N4400ZX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRYS","BK4082","BK4139","PSCH","CLPT","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656301205","title":"GeneDx Q2 Revenue Beats Analyst Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2656301205","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656301205?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:12","pubTimestamp":1785787943,"startTime":"0","endTime":"0","summary":"GeneDx Q2 revenue beats analyst estimatesOverviewU.S. rare disease genomics tester's Q2 revenue grew 11% yr/yr, beating analyst expectationsAdjusted net income was $0.4 mln, up from a loss in the prio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL1N4400Z6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","BK4139","WGS","HELX","KRYS","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656303023","title":"Krystal Biotech Down Nearly 12%, on Pace for Largest Percent Decrease Since August 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2656303023","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656303023?lang=en_us&edition=fundamental","pubTime":"2026-08-04 01:25","pubTimestamp":1785777900,"startTime":"0","endTime":"0","summary":"Krystal Biotech, Inc.  is currently at $300.76, down $40.37 or 11.83%--Would be lowest close since June 2, 2026, when it closed at $293.21--On pace for largest percent decrease since Aug. 4, 2025, when it fell 14.04%--Currently down three of the past four days--Currently down two consecutive days; down 18.02% over this period--Worst two day stretch since the two days ending May 9, 2022, when it fell 21.35%--Up 21.99% year-to-date--Down 20.47% from its all-time closing high of $378.15 on June 29, 2026--Up 122.88% from 52 weeks ago , when it closed at $134.94--Down 20.47% from its 52-week closing high of $378.15 on June 29, 2026--Up 122.88% from its 52-week closing low of $134.94 on Aug. 4, 2025--Traded as low as $297.02; lowest intraday level since June 3, 2026, when it hit $290.04--Down 12.93% at today's intraday low; largest intraday percent decrease since Aug. 4, 2025, when it fell as much as 16.87%All data as of 1:20:00 PM ETSource: Dow Jones Market Data, FactSet","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HELX","BK4585","BK4588","KRYS","BK4139","XBI","BK4581","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656330819","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2656330819","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656330819?lang=en_us&edition=fundamental","pubTime":"2026-08-04 00:00","pubTimestamp":1785772852,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Opus Genetics (IRD) and Krystal Biotech (KRYS) with ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-271?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-271?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","HELX","KRYS","IRD","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656697372","title":"Analysts Conflicted on These Healthcare Names: Guardant Health (GH) and Cardinal Health (CAH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2656697372","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656697372?lang=en_us&edition=fundamental","pubTime":"2026-08-03 22:00","pubTimestamp":1785765628,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Guardant Health (GH) and Cardinal Health (CAH). Gu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-guardant-health-gh-and-cardinal-health-cah-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-guardant-health-gh-and-cardinal-health-cah-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0310800965.SGD","LU0889566641.SGD","EKG","LU0320765992.SGD","LU1267930227.SGD","BK4551","LU1267930813.SGD","LU0128525689.USD","LU0029874061.USD","LU1267930490.SGD","GH","LU0889565916.HKD","LU1880398471.USD","BK4585","LU1983299246.USD","LU0006061336.USD","BK4581","SG9999001440.SGD","BK4175","GNMX","BK4137","HELX","LU1571399168.USD","LU0310799852.SGD","XLV","LABU","FFOX","LU0211328371.USD","LU0128526141.USD","BK4588","LU0072461881.USD","PTH","LU0154236417.USD","CAH","LU0211327993.USD","LU0162691827.USD","GNOM","BK4196","LU0052756011.USD","GDOC","LU1880398554.USD","LU0792757196.USD","HCSG","LFSC","LU0109394709.USD","BK4535","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656374922","title":"Krystal Biotech Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2656374922","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656374922?lang=en_us&edition=fundamental","pubTime":"2026-08-03 21:31","pubTimestamp":1785763905,"startTime":"0","endTime":"0","summary":"Krystal Biotech Inc reports results for the quarter ended June 30 - Earnings SummaryKrystal Biotech IncKRYS.OQreported quarterly adjusted earnings of $1.79 per share for the quarter ended June 30, hig","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL8N4401GJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KRYS","PSCH","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656866379","title":"Design Therapeutics Q2 Net Loss Narrower than Expected","url":"https://stock-news.laohu8.com/highlight/detail?id=2656866379","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656866379?lang=en_us&edition=fundamental","pubTime":"2026-08-03 20:15","pubTimestamp":1785759346,"startTime":"0","endTime":"0","summary":"Design Therapeutics Q2 net loss narrower than expectedOverviewUS biotech firm's Q2 net loss was lower than analyst expectationsOperating expenses for Q2 totaled $22.2 mlnCompany ended Q2 with $207.4 m","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL1N4400FA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4539","TGTX","BK4007","KRYS","BK4585","BK4139","BK4505","HELX","OCUL","DSGN","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656375311","title":"Ocular Therapeutix Q2 Product Revenue Flat, Net Loss Widens on Higher Spending","url":"https://stock-news.laohu8.com/highlight/detail?id=2656375311","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656375311?lang=en_us&edition=fundamental","pubTime":"2026-08-03 19:21","pubTimestamp":1785756090,"startTime":"0","endTime":"0","summary":"Ocular Therapeutix Q2 product revenue flat, net loss widens on higher spendingOverviewUS biopharmaceutical firm's Q2 product revenue was flat yr/yrNet loss for Q2 widened compared to prior yearCompany","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL1N4400DI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4501","BK4568","OCUL","TGTX","BK4551","BK4585","BK4534","PSCH","BK4533","BK4588","LGHT","IDNA","BK4139","BK4007","KRYS","MRNX","HELX","MRNA","BK4548","WDNA","MRNY","BK4532","GNOM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656373795","title":"Krystal Biotech Q2 Revenue Rises on Vyjuvek Strength","url":"https://stock-news.laohu8.com/highlight/detail?id=2656373795","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656373795?lang=en_us&edition=fundamental","pubTime":"2026-08-03 19:12","pubTimestamp":1785755552,"startTime":"0","endTime":"0","summary":"Krystal Biotech Q2 revenue rises on VYJUVEK strengthOverviewUS genetic medicines developer's Q2 product revenue grew 24% yr/yr to $119.2 mlnAdjusted EPS for Q2 rose to $1.79 from $1.29 a year agoCompa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL1N4400D3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0511384066.AUD","LU1244550221.USD","LU0456855351.SGD","LU2089284900.SGD","AGNG","PPH","RXL","GLAM","LU0234572021.USD","LU1732799900.SGD","LU2237443465.HKD","MRNX","ABBV","LU0553294199.USD","MRNY","SG9999015945.SGD","IE00BVYPNW00.USD","KRYS","IE00BGHQF631.EUR","WDNA","IYH","LU0320765646.SGD","MRNA","TRUH","LU2129689514.USD","LU1923622614.USD","IE0002270589.USD","MEDX","BK4581","GNOM","IDNA","FHLC","IXJ","LU1934455863.HKD","VHT","LU2237443622.USD","PJP","XLV","IE00BJT1NW94.SGD","PSCH","JDOC","LU2089283258.USD","LU2357627491.SGD","LU0859254822.USD","LGHT","HELX","LU1061106388.HKD","IE00B19Z3B42.SGD","FTXH","IE00BLSP4239.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656732883","title":"Krystal Biotech Shares Down 5.8% Premarket After Q2 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2656732883","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656732883?lang=en_us&edition=fundamental","pubTime":"2026-08-03 19:08","pubTimestamp":1785755312,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL4N4400XE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KRYS","HELX","PSCH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656373454","title":"Krystal Biotech Q2 Net Income Rises 43% to $54.8 Million; Revenue Climbs 24% to $119.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2656373454","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656373454?lang=en_us&edition=fundamental","pubTime":"2026-08-03 19:05","pubTimestamp":1785755120,"startTime":"0","endTime":"0","summary":"Krystal Biotech Q2 net income rises 43% to $54.8 million; revenue climbs 24% to $119.2 millionKrystal Biotech posted 2Q net income of $54.8 million, or $1.79 per diluted share, up from $38.3 million a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDL68yNBG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","LU0314104364.USD","PSCH","HELX","SG9999014005.SGD","BK4588","SG9999014021.USD","IE00BGHQF748.EUR","SG9999014039.USD","IE00BKPKM429.USD","BK4585","LU2095319765.USD","BK4112","BK4139","IE00B64PRP62.GBP","IE00BN0W2W23.USD","SG9999014013.SGD","IE00B3QW5Z07.USD","NDAQ","LU2210149790.SGD","KRYS","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656437355","title":"Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2656437355","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656437355?lang=en_us&edition=fundamental","pubTime":"2026-08-03 19:00","pubTimestamp":1785754801,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nTUA9HCNB6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HELX","PSCH","KRYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656437394","title":"Krystal Biotech - Sees FY 2026 Non-Gaap R&D and SG&a Expense $175 Mln-$195 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2656437394","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656437394?lang=en_us&edition=fundamental","pubTime":"2026-08-03 19:00","pubTimestamp":1785754801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nPLXZ8VXL2:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HELX","PSCH","BK4139","KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656237352","title":"Krystal Biotech Q2 Product Revenue USD 119.222 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2656237352","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656237352?lang=en_us&edition=fundamental","pubTime":"2026-08-03 19:00","pubTimestamp":1785754801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nPLXZ8VXL2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KRYS","BK4139","HELX","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655885398","title":"Guardant Health Shares Climb Following Outlook Raise","url":"https://stock-news.laohu8.com/highlight/detail?id=2655885398","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655885398?lang=en_us&edition=fundamental","pubTime":"2026-07-31 23:54","pubTimestamp":1785513240,"startTime":"0","endTime":"0","summary":"Shares of Guardant Health are trading higher after the company raised its full-year revenue outlook and reported higher-than-expected sales during the second quarter.The stock rose 6.1%, to $161.69, o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH","BK4588","BK4535","GDOC","FFOX","LU0889565916.HKD","PTH","GNMX","HELX","LU0109394709.USD","LU0320765992.SGD","BK4196","BK4585","BK4551","GNOM","EKG","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655912361","title":"RBC Raises Price Target on Guardant Health to $200 From $185, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2655912361","media":"MT Newswires Live","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655912361?lang=en_us&edition=fundamental","pubTime":"2026-07-31 21:16","pubTimestamp":1785503760,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) has an average rating of buy and mean price target of $191.09, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major bank","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GH","GNMX","LU0320765992.SGD","LFSC","GNOM","BK4585","HELX","FFOX","BK4588","LU0889565916.HKD","LU0109394709.USD","EKG","BK4535","BK4196","GDOC","BK4551","PTH"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":10,"totalSize":200,"code":"91000000","status":"200"}]}}